Show summary Hide summary
Hims earnings delivered a shocking twist this evening: $608M revenue growth masked a $92M surprise loss. The telemedicine giant raised 2026 guidance despite red ink, signaling management confidence in its recovery. But the question haunting investors is whether restructuring charges now give way to genuine profitability.
🔥 Quick Facts
- Q1 Revenue: $608.1 million, up 4% year-over-year versus $586.0 million in Q1 2025
- Net Loss Surprise: $92.1 million ($0.40 per share loss) versus $49.5 million profit year-ago
- Subscriber Growth: Nearly 2.6 million subscribers, up 9% year-over-year in Q1
- Raised Guidance: Full year 2026 revenue guidance raised to $2.8B to $3.0B versus prior $2.7B to $2.9B
The Earnings Paradox: Growth Meets Restructuring Costs
Hims & Hers Health reported May 11, 2026 results that exemplify the telehealth sector’s conflicting signals. Revenue climbed steadily, reaching $608.1 million, but the company absorbed strategic restructuring charges that flipped the year-ago profit into a substantial loss. The $92.1 million net loss represents a dramatic swing from last year’s $49.5 million profit. Management expects these charges represent a one-time event, not a trend.
The paradox reflects Hims‘ pivot away from high-margin compounded GLP-1 weight loss drugs following regulatory scrutiny. While the company gains 9% more subscribers, gross margin compression signals the gap left by that business shift. Adjusted EBITDA stands as the truer measure of operational health, though even that disappoints relative to analyst expectations.
Breeze Airways launches 5 new international routes in Caribbean
Roaring Kitty’s X account posts after 16 months, GameStop jumps 13%
Guidance Raised, but EBITDA Outlook Trails Estimates
Hims lifted its 2026 full-year revenue guidance to a range of $2.8 billion to $3.0 billion, up from prior guidance of $2.7 billion to $2.9 billion. This move signals management confidence in personalized healthcare demand. However, adjusted EBITDA guidance of $275 million to $350 million fell below the $322.8 million analyst consensus, creating disappointment in after-hours trading.
For Q2 2026, the company guides revenue of $680 million to $700 million, meaningfully above the $642.95 million analyst average. This sequential confidence suggests the worst of regulatory headwinds may have passed. The company also generated $53 million in free cash flow during the quarter, proving underlying operations remain healthy despite accounting losses.
Subscriber Base Expanding While Margins Compress
| Metric | Q1 2026 | Q1 2025 |
| Revenue | $608.1 million | $586.0 million |
| Year-over-Year Growth | 4% | Baseline |
| Net Income (Loss) | ($92.1 million) | $49.5 million |
| Subscribers | 2.6 million | 2.38 million |
| Subscriber Growth | +9% YoY | Baseline |
“These results reinforce our confidence in our 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.”
— According to Hims management in the Q1 2026 earnings release
FDA Regulatory Headwinds Ease as Company Diversifies Beyond GLP-1
Hims faced formidable FDA regulatory pressure on compounded weight loss medications earlier in 2026. The suppression of that high-margin business created the net loss despite revenue growth. However, guidance improvements suggest the company successfully diversified its portfolio, expanding telehealth services for chronic conditions, sexual health, and primary care.
The $53 million free cash flow generation proves the core business remains profitable despite reported losses. Management expects restructuring charges to complete, allowing normalized profitability to emerge by Q2 and beyond. The firm also pursued a $250 million share buyback program, signaling confidence in long-term value creation and management’s belief the stock trades below intrinsic worth.
What Happens Next: Will Hims Recover?
The real test begins now. Q2 guidance of $680 million to $700 million runs well ahead of analyst estimates, suggesting momentum. If the company delivers, the narrative shifts from margin compression crisis to successful business model evolution. Management’s 2030 targets of $6.5 billion revenue and $1.3 billion EBITDA require sustained execution.
Stock investors clearly punished the surprise loss, but the raised full-year guidance and improved Q2 outlook may attract longer-term buyers. The combination of 2.6 million growing subscribers, $53 million quarterly FCF, and powerful EBITDA recovery expectations suggests management may have finally turned the corner. Watch for Hims to prove it on the Q2 earnings call, where management must defend why EBITDA guidance trails consensus even as revenue beats expectations.
Sources
- HIMS Investor Relations – Official Q1 2026 earnings report released May 11, 2026
- Reuters, Yahoo Finance, Investing.com – Real-time market reaction and earnings updates
- TradingView, Sherwood.news – Financial analysis and guidance reconciliation
